VivoSim Taps Pharma Sales Veteran to Drive Adoption of Liver, GI Toxicity Models
Event summary
- VivoSim Labs appointed Dr. Arumugham (Ragoo) Raghunathan as VP of Global Sales on March 3, 2026.
- Raghunathan will lead commercial expansion and strategic partnerships in preclinical safety solutions.
- Focus areas include liver and gastrointestinal (GI) toxicity solutions for drug development.
- VivoSim aims to accelerate adoption of its New Approach Methodologies (NAMs) following FDA's 2025 animal testing refinements.
The big picture
VivoSim’s appointment of Raghunathan underscores its push to capitalize on regulatory and market shifts favoring in vitro toxicology. The move aligns with broader industry trends toward reducing late-stage drug candidate failures through earlier, more predictive safety assessments. With the FDA’s 2025 refinements to animal testing requirements, VivoSim is positioning itself as a key player in the transition to NAMs, targeting biotech startups and large pharma portfolios alike.
What we're watching
- Commercial Execution
- How Raghunathan’s track record in consultative sales will translate to VivoSim’s adoption rates among biopharma and CROs.
- Regulatory Tailwinds
- The pace at which FDA’s 2025 NAMs guidance accelerates industry-wide shift from animal testing to in vitro models.
- Market Differentiation
- Whether VivoSim can sustain competitive edge in liver and GI toxicity prediction amid growing demand for human-relevant toxicology.